Alira Health

Alira Health

We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

News
Category:
Published on:
December 20, 2020

Alira Health is pleased to announce its role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.

Merieux Equity Partners is a global asset manager specialized in the healthcare and nutrition sectors. Cell-Easy is a novel French pharmaceutical laboratory specialized in the development and manufacturing of novel cell therapies for preclinical and clinical studies. This fund raising aims at accelerating the company’s growth in France and internationally, by expanding the Cell-Easy Management Team and strengthening the company’s commercial presence in key regions.

To read the press release on BusinessWire, click here.

For more information, contact Joris Pezzini.

For more information about Alira Health Transaction Advisory services

Click here

Aenean ut neque vehicula, iaculis odio ut, porta risus. In gravida libero faucibus ex vulputate pharetra. Donec sed sapien odio. Donec vel pellentesque eros. Aliquam erat volutpat. Suspendisse luctus massa accumsan, egestas lacus ac, aliquam libero. Praesent mollis magna vel mi fermentum pulvinar. Fusce quis ultricies sapien, eu suscipit ligula. Duis ut enim ac felis scelerisque sodales. Quisque a elit ac mi cursus posuere vitae sed augue. Nunc varius a ex eget posuere. Nullam fringilla aliquet diam. Maecenas mattis ac massa id fermentum. Proin convallis dui sit amet urna volutpat, ac rutrum magna volutpat. Sed gravida tincidunt laoreet. Nulla nec enim vitae nulla vehicula tempus.

Related news

Case Studies March 26, 2024
Pharma Company Overcomes Launch Challenges with Patient-Centric Strategy
Our patient engagement team helped this pharma client identify the drivers behind the challenges they faced with their product launch.
Patient Centricity Patient Engagement Pharma
Case Studies March 12, 2024
Pharma Company Adopts a Patient-Centric Value Proposition for Regulatory and Payer Dossier
A pharma company had a wealth of patient data on a product in development and they wanted to create a long-term strategy that would create a continuity of patient engagement across(...)
Patient Centricity Patient Engagement Pharma
News February 7, 2024
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Pharma Transaction Advisory
News January 26, 2024
Alira Health’s CDD Supports Alcami Acquisition of Pacific Pharmaceutical Services
We are pleased to have been an advisor on Alcami’s acquisition of Pacific Pharmaceutical Services (PPS). Alira Health advised Alcami, a leading Contract Development Manufacturing(...)
CDD CDMO Pharma
Events January 22, 2024
Pharmapack Europe
Connect with our Drug Delivery Systems and CDMO experts Aude Ouensanga, Giulia Valsecchi, and Michal Raciborski on site at Pharmapack Europe.
CDMO Drug Delivery Pharma
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
Case Studies January 8, 2024
Pharma Company Extends to New Markets through Strategic Licensing Agreements
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
Market Access Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.